The House Energy & Commerce Committee will consider seven pieces of drug-pricing transparency legislation at a hearing on May 21, the committee announced Friday (May 17). The seven bills are: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. H.R. 2069, which mirrors a measure introduced by Senate Finance ranking Democrat Ron Wyden (OR), would make drug companies justify price increases. The bill outlines two thresholds to trigger reporting: dramatic price increases, or moderate increases for drugs on...